By Colin Kellaher
Kenvue has struck a cooperation agreement with Starboard Value, averting a proxy fight with the activist investment firm.
Kenvue on Wednesday said it has added three new board members, including Starboard chief Jeffrey Smith, who has expressed disappointment with the consumer health company's management and share-price performance.
Smith last year said that Kenvue, the maker of Band-Aids and Tylenol that was spun out from Johnson & Johnson in 2023, should drill down on fixing its underperforming skin health and beauty segment and on improving the company's marketing strategy.
Starboard last month nominated a slate of four director candidates, including Smith, in a bid to reconstitute Kenvue's board.
Kenvue said it added Smith, along with independent directors Sarah Hofstetter and Erica Mann, to its board, and that Starboard will withdraw its nominees and vote its shares in favor of the Skillman, N.J., company's board slate at this year's annual meeting. Hofstetter is president of e-commerce insights platform Profitero, while Mann is a former head of Bayer's consumer-health division.
Kenvue said its board will temporarily expand to 14 directors from 11 before being reduced to 13 directors at the annual meeting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 05, 2025 08:45 ET (13:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。